Track market-moving stories before they get noisy

, /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Calix, Inc. ("Calix" or the "Company") (NYSE: CALX).

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CALIX, INC. (CALX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JULY 27, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at [email protected], by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Is The Lawsuit About?
The complaint filed alleges that, between January 28, 2026 and April 21, 2026, Defendants failed to disclose to investors: (1) the Company's first quarter margins had significantly benefited from advanced purchasing of memory components; (2) that the Company's advanced supply of memory components was dwindling; (3) that, as a result, the Company was experiencing negative margin pressure as it was forced to purchase memory components at rising market prices; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's margins, business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact:
Howard G. Smith, Esq.,
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Call us at: (215) 638-4847
Email us at: [email protected],
Visit our website at: www.howardsmithlaw.com.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
[email protected]
www.howardsmithlaw.com

SOURCE Law Offices of Howard G. Smith

-

Following the successful launch of secure, agentic workflows on the AI-native Calix One platform for its 1,200 customers in May 2026, Newsweek—along with Fortune, Glassdoor, and Comparably—recognizes Calix for a culture of innovation that enables customers to transform their operations and accelerate experiences to compete and win in any market

SAN JOSE, Calif.--(BUSINESS WIRE)--Today, Calix, Inc. (NYSE: CALX) announced it has received 4.5 out of 5 stars in Newsweek’s annual “Greatest Workplaces in Tech” list, which ranks companies based on leadership, fair compensation, and work-life balance—with particular consideration made of teams who incorporate responsible use of AI to support rather than supplant their employees. Calix also ranked last year on the Newsweek list, earning 4 out of 5 stars.

“Our focus is on empowering our people with AI, not replacing them. When every employee applies safe, secure, and empowering AI to their daily work, it becomes a force multiplier for how we execute and serve our customers," said John Durocher, Calix COO.

ShareThis recognition adds to the growing list of culture and leadership honors Calix has earned from Fortune, Glassdoor, and Comparably, reflecting the company’s commitment to transformational innovation under the leadership of CEO Michael Weening, a 2024 and 2025 Comparably Top CEO, and Chief Product Officer Shane Eleniak, a recipient of the Global CPO Top 20 Award.

The Calix culture has turned 15 years and more than $2 billion in investment into the AI-native Calix One™ platform, which supports its customers by running more than 4.3 billion workflows and operations annually and ingesting more than a petabyte of data daily. Calix One enables service providers of all sizes to improve subscriber experience, reduce call center churn, and grow revenue—while lowering operating costs. The latest advancements for the platform, launched in May, allow providers to orchestrate agentic workflows that result in breakthrough gains in subscriber loyalty, operational efficiency, and revenue.

Within the company, Calix is operationalizing secure agentic AI by embedding it into everyday work. With approximately 98 percent employee adoption of Microsoft Copilot, more than 400 employee-built enterprise agents, and over 20,000 monthly interactions, AI is supporting real workflows across the business—accelerating execution, surfacing insights, reducing manual analysis, and driving an estimated $37 million in annual productivity gains.

John Durocher, chief operations officer at Calix, said: “Our focus is on empowering our people with AI, not replacing them. When every employee applies safe, secure, and empowering AI to their daily work, it becomes a force multiplier for how we execute and serve our customers. That is how we turn human potential into real business outcomes.”

The Newsweek honor is the latest in a number of 2026 culture-based awards for Calix:

Best Companies to Work For® (Fortune, No. 85/100)Best Workplaces in Technology (Fortune, No. 21/100)Best Companies to Work For® in the Bay Area (Fortune, No. 18/100)Best Workplaces for Parents (Fortune, No. 67/100)Best Companies in Tech & AI (Glassdoor, No. 22/25)Best Places to Work (Glassdoor, No. 88/100)Best Company Outlook (Comparably, No. 1/100)Best Companies for Diversity (Comparably, No. 9/100)Best Leadership Teams (Comparably, No. 10/50)Best Companies for Women (Comparably, No. 14/100)Best Companies for Career Growth (Comparably, No. 20/50)Best HR Teams (Comparably, No. 4/25)Best Engineering Teams (Comparably, No. 7/25)Best Sales Teams (Comparably, No. 8/25)Top Rated Sales Orgs at Public Companies (Reppy Award)Best Workplaces with Most Trusted Executive Team (Great Place To Work Canada)Best Marketing Teams (Comparably, No. 3/25)Michael Weening, president and chief executive officer at Calix, said: “We started investing in agentic AI in November 2023—building on more than 26 years of trusted customer partnerships and our deep understanding of their workflows—to enable every customer to make the most of the AI opportunity and empower their teams, subscribers, and the communities they serve. Supported by our platform and partnership with Google Cloud, customers like ALLO, CentraNet, RTC, and Tombigbee have launched agentic workflows that are safe and secure and that empower team members—with early success in optimizing onboarding and troubleshooting. The Newsweek honor and awards from Fortune and Comparably are a testament to our teams’ trusted partnerships with customers. They signal a bright future ahead as we continue our AI journey safely, securely, and with human empowerment front and center, together.”

Learn more about Calix One and the company’s award-winning culture.

About Calix

Calix, Inc. (NYSE: CALX) is an AI platform company that enables service providers to transform their operations and accelerate delivery of differentiated experiences—so they can compete and win in the markets and communities they serve.

Through the AI-native Calix One platform, service providers can securely and privately activate agentic AI alongside their human teams to acquire new subscribers, grow existing subscriber revenue, and build loyalty across residential, business, municipal, and MDU markets. More than 1,200 customers of all sizes leverage the Calix One platform, which has evolved over 15 years at an investment of more than $2 billion.

Calix innovation cycles are underpinned by a strong financial balance sheet and a people-first culture that routinely earns broad industry recognition—winning 81 culture and innovation awards since 2025 alone, as well as Fortune’s 100 Best Companies to Work For® in 2026. This press release contains forward-looking statements that are based upon management’s current expectations and are inherently uncertain. Forward-looking statements are based upon information available to us as of the date of this release, and we assume no obligation to revise or update any such forward-looking statement to reflect any event or circumstance after the date of this release, except as required by law. Actual results and the timing of events could differ materially from current expectations based on risks and uncertainties affecting Calix’s business. The reader is cautioned not to rely on the forward-looking statements contained in this press release. Additional information on potential factors that could affect Calix’s results and other risks and uncertainties are detailed in its quarterly reports on Form 10-Q and Annual Report on Form 10-K filed with the SEC and available at www.sec.gov.

Calix and the Calix logo are trademarks or registered trademarks of Calix and/or its affiliates in the U.S. and other countries. A listing of Calix’s trademarks can be found at https://www.calix.com/legal/trademarks.html. Third-party trademarks mentioned are the property of their respective owners.

More News From Calix, Inc.

Back to Newsroom

Important Information Regarding Section 20(a) Individual Liability Claims Against Calix CEO and CFO Who Allegedly Concealed Exhaustion of Low-Cost Memory Supply While Touting Record Margins

, /PRNewswire/ -- Two senior executives of Calix, Inc. (NYSE: CALX) are named as individual defendants in a securities class action alleging they personally controlled the dissemination of materially misleading statements about the Company's gross margins during the period from January 28, 2026 through April 21, 2026. Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

When the truth emerged on April 21, 2026, CALX shares fell $6.93 per share, a decline of 13.98%, closing at $42.65 the following day on unusually heavy volume. The Court has set July 27, 2026 as the deadline to apply for lead plaintiff appointment.

The Named Individual Defendants

The complaint identifies the following officers as individually liable:

Michael Weening, Chief Executive Officer at all relevant times, who possessed the power and authority to control the contents of SEC filings, press releases, and presentations to analysts and institutional investors Cory Sindelar, Chief Financial Officer at all relevant times, who oversaw financial reporting and participated in earnings communications where the concealed "advanced purchasing" strategy was eventually disclosed Both defendants are alleged to have had access to material non-public information regarding the Company's dwindling supply of lower-cost memory components and the imminent margin pressure that information implied.

Section 20(a) Control Person Framework

The action asserts claims under Section 20(a) of the Securities Exchange Act of 1934, which imposes liability on individuals who "controlled" the entity that violated federal securities laws. The complaint contends that by virtue of their high-level positions, both Weening and Sindelar:

Had direct supervisory involvement in day-to-day operations Influenced and controlled the content of SEC filings and press releases issued during the Class Period Were provided with or had unlimited access to Company reports and public statements prior to issuance Had the ability to prevent misleading statements or cause them to be corrected Were privy to internal data reflecting the true state of the Company's memory component supply and cost trajectory Sarbanes-Oxley Certification Obligations

Under Sections 302 and 906 of the Sarbanes-Oxley Act, both the CEO and CFO personally certified the accuracy of the Company's Form 10-K for the period ended December 31, 2025, filed on February 20, 2026. The complaint alleges these certifications were made while the Company's advanced supply of memory components was already dwindling, meaning the record 58% non-GAAP gross margin figure reported for Q4 2025 was sustained by a temporary procurement advantage that defendants knew was nearing exhaustion.

"Corporate officers have a duty to ensure their companies' public statements are accurate and complete. When executives certify financial reports under Sarbanes-Oxley, they assume personal responsibility for the information those filings contain and what they omit." -- Joseph E. Levi, Esq.

Speak with an attorney about your options or call (888) SueWallSt.

About SueWallSt

SueWallSt -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the CALX Lawsuit

Q: Who are the defendants named in the CALX lawsuit? A: The complaint names Calix, Inc. and individual defendants CEO Michael Weening and CFO Cory Sindelar, who signed SEC filings and made or controlled public statements during the Class Period.

Q: What is the CALX lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is July 27, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I already sold my CALX shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the Class Period and sold at a loss may still participate.

Q: How do I know if I lost enough money to be the lead plaintiff? A: There is no minimum loss threshold. Courts appoint the investor with the largest provable loss who is willing and able to represent the class adequately. Contact SueWallSt before July 27, 2026 to evaluate.

Q: What documents do I need to make a claim? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

CONTACT:

SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171

SOURCE SueWallSt.com

Today, [url="]Calix, Inc.[/url] (NYSE: CALX) announced it has received 4.5 out of 5 stars in Newsweek's annual [url="]“Greatest Workplaces in Tech” list[/ur

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Calix, Inc. (NYSE: CALX) between January 28, 2026 and April 21, 2026, inclusive (the “Class Period”), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Calix securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Calix's first quarter margins had significantly benefited from advanced purchasing of memory components; (2) Calix's advanced supply of memory components was dwindling; (3) as a result, Calix was experiencing negative margin pressure as it was forced to purchase memory components at rising market prices; and (4) as a result of the foregoing, defendants' positive statements about Calix's margins, business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

New York, New York--(Newsfile Corp. - June 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Calix, Inc. (NYSE: CALX) between January 28, 2026 and April 21, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Calix securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 27, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Calix's first quarter margins had significantly benefited from advanced purchasing of memory components; (2) Calix's advanced supply of memory components was dwindling; (3) as a result, Calix was experiencing negative margin pressure as it was forced to purchase memory components at rising market prices; and (4) as a result of the foregoing, defendants' positive statements about Calix's margins, business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Calix class action, go to https://rosenlegal.com/cases/calix-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302178

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

CALX Deadline: CALX Investors with Losses in Excess of $100K Have Opportunity to Lead Calix, Inc. Securities Fraud Lawsuit PR N

Creates a scaled BDC positioned for growth while maintaining industry leading credit quality and portfolio yield June 18, 2026 07:00 ET  | Source: Chicago Atlantic BDC, Inc.; Chicago Atlantic Real Estate Finance, Inc.

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Chicago Atlantic Real Estate Finance, Inc. (“REFI”) (NASDAQ: REFI), a commercial mortgage real estate investment trust, and Chicago Atlantic BDC, Inc. (the “LIEN”) (NASDAQ: LIEN), a specialty finance company that has elected to be regulated as a business development company (“BDC”), today announced they have entered into a definitive merger agreement (the “Merger Agreement”) under which REFI will elect to be regulated as a BDC, and merge with and into LIEN in an all-stock, strategic combination (the “Merger”). Upon closing of the Merger, LIEN will be the surviving public entity and will continue to operate as a BDC and trade on the Nasdaq Global Select Market under the ticker symbol “LIEN.”

The Board of Directors of both companies, each acting on the unanimous recommendation of their respective special committee comprised solely of independent directors, unanimously approved the Merger Agreement and the transactions contemplated thereby. Under the terms of the Merger Agreement, REFI stockholders will receive a number of shares of LIEN common stock based on the ratio of REFI's adjusted net asset value ("NAV") per share to LIEN's adjusted NAV per share, in each case as determined shortly prior to closing in accordance with the Merger Agreement. Based on the respective net asset values of REFI and LIEN as of March 31, 2026, the former REFI stockholders would be expected to own approximately 50.5% of LIEN immediately following the Merger; the actual ownership percentage will depend on the NAV ratio calculated shortly prior to closing. The Merger is structured as an adjusted NAV-for-NAV exchange of shares.

Peter Sack, Co-Chief Executive Officer of REFI and, Chief Executive Officer of LIEN stated “The merger of REFI and LIEN brings together two platforms with a shared foundation of disciplined, senior secured lending to the cannabis industry and underserved segments of the lower middle markets. For REFI, this transaction is a path to unlock value that would be difficult to achieve independently in the current evolving cannabis investment landscape. For LIEN, this transaction accelerates the core strategy.” Mr. Sack continued, “Together, we believe the combined platform will be better positioned to pursue attractive risk-adjusted returns across cannabis and the broader lower middle market.”

Scott Gordon, Executive Chairman of the Board of Directors of LIEN remarked, “The merger of REFI and LIEN is a strategic transaction that we believe will enhance value for stockholders. We view this as an important step on our path to pursuing greater scale, supporting earnings over time and maintaining strong credit quality for the combined company.”

Strategic Benefits of the Merger:

Increases Competitive Positioning – The Merger creates a vehicle with a pro-forma NAV of $613 million1, and a pro-forma portfolio of $771 million1 in investments, which the parties believe could expand the combined company's reach with a broader universe of borrowers.Enhances Portfolio Diversification and Collateral Base – The pro forma vehicle is expected to include an attractive mix of cash-flow loans, real estate–backed loans, and diversified direct lending.Improves Access to Debt Capital – Increased scale is expected to expand access to larger, lower-cost, and more diversified leverage, which the boards believe could support more efficient balance sheet management over time, driving incremental earnings.Enhances Liquidity and Investor Visibility – Increased scale may support improved trading liquidity, increased institutional engagement and visibility.Potential for Earnings Accretion–The boards believe the combination has the potential to drive operating efficiencies through the elimination of overlapping expense categories and may support increased earnings capacity over time through prudent use of leverage.Strong Pro Forma Portfolio Metrics – Results in a pro-forma portfolio with strong credit metrics, reflecting the aligned investment and underwriting philosophies of the combined platforms.Stock Repurchase Program – The Merger agreement provides that the LIEN board will consider in good faith, the adoption of a stock repurchase program of up to $25.0 million to be implemented following the closing of the transaction, subject to market conditions and other factors the LIEN Board determines to be relevant at that time.
Management and Governance

Chicago Atlantic BDC Advisers, LLC, a majority-owned subsidiary of Chicago Atlantic Group, LP, will continue to serve as the investment adviser of LIEN following the closing of the Merger.

Peter Sack will lead the combined company as Chief Executive Officer. Following the closing of the transaction, the LIEN Board of Directors will include three independent directors continuing from REFI and two independent directors continuing from LIEN, along with two directors affiliated with the LIEN Adviser or its affiliates (subject to finalization in accordance with the Merger Agreement and applicable Investment Company Act requirements).

Required Approvals and Expected Timing

Completion of the Merger is subject to the approval of stockholders of both REFI and LIEN, as well as regulatory approvals, lender consents and other customary closing conditions. Subject to the satisfaction of the conditions of the transaction, the Merger is currently expected to close in the fourth quarter of 2026. Chicago Atlantic has agreed to fund $2.0 million of REFI’s transaction-related expenses in connection with the transaction at or immediately prior to closing, underscoring its commitment to the transaction.

Transaction Advisors

Oppenheimer & Co. is serving as financial advisor, and Nixon Peabody LLP is serving as legal counsel to the Special Committee of independent directors of REFI.

Keefe, Bruyette & Woods, A Stifel Company, is serving as financial advisor, and Eversheds Sutherland is serving as legal counsel to the Special Committee of independent directors of LIEN.

Conference Call and Related Presentation

A joint conference call will be held at 9:00 a.m. ET on Thursday, June 18, 2026. A live webcast of the conference call and associated presentation material will be available on the investor relations section of each company’s website at investors.refi.reit and investors.chicagoatlanticbdc.com A replay of the call will be available at the end of the day at the same locations.

Call Details:

When: Thursday, June 18, 2026Time: 9:00 a.m. ETConference call dial-in: 877-317-6789 and 412-317-6789 for international callersWebcast Live Stream: https://event.choruscall.com/mediaframe/webcast.html?webcastid=cm4KYEzO About Chicago Atlantic Real Estate Finance, Inc.

Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) is a market-leading commercial mortgage REIT utilizing significant real estate, credit and cannabis expertise to originate senior secured loans primarily to state-licensed cannabis operators in limited-license states in the United States. REFI is managed by Chicago Atlantic REIT Manager, LLC, an investment manager focused on the cannabis industry and other niche or underfollowed sectors, please visit https://www.refi.reit/.

About Chicago Atlantic BDC, Inc.

Chicago Atlantic BDC, Inc. (Nasdaq: LIEN) is a specialty finance company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended, and has elected to be treated as a regulated investment company for U.S. federal income tax purposes. LIEN’s investment objective is to maximize risk-adjusted returns on equity for its stockholders by investing primarily in direct loans to privately held middle-market companies, with a primary focus on cannabis companies. LIEN is managed by Chicago Atlantic BDC Advisers, LLC, an investment manager focused on the cannabis industry and other niche or underfollowed sectors. For more information, please visit https://investors.chicagoatlanticbdc.com/.

Forward-Looking Statements

Some of the statements in this communication constitute forward-looking statements because they relate to future events, future performance or financial condition of REFI, LIEN or the Merger. Forward-looking statements may include statements as to: future operating results of the combined company and distribution projections; business prospects of the combined company and the prospects of its portfolio companies; and the impact of the investments that the combined company expects to make. In addition, words such as “may,” “might,” “will,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “estimate,” “anticipate,” “predict,” “potential,” “plan” or similar words indicate forward-looking statements. The forward-looking statements contained in this communication involve risks and uncertainties. Certain factors could cause actual results and conditions to differ materially from those projected, including the uncertainties associated with (i) the ability of the parties to consummate the Merger on the expected timeline, or at all; (ii) the ability to realize the anticipated benefits of the Merger; (iii) the percentage of LIEN and REFI stockholders voting in favor of the proposals submitted for their approval; (iv) the possibility that competing offers or acquisition proposals will be made; (v) the possibility that any or all of the various conditions to the consummation of the Merger may not be satisfied or waived; (vi) risks related to diverting management’s attention from ongoing business operations; (vii) the risk that stockholder litigation in connection with the Merger may result in significant costs of defense and liability; (viii) changes in the economy, financial markets, and political environment; (ix) future changes in laws or regulations, including laws applicable to the cannabis industry; (x) the risk that the Merger may not qualify as a "reorganization" within the meaning of Section 368(a) of the Internal Revenue Code; (xi) the risk that the surviving company may not qualify or maintain its qualification as a regulated investment company for U.S. federal income tax purposes; (xii) the risk that REFI may fail to maintain its qualification as a real estate investment trust through the effective time of the Merger; (xiii) the risk that REFI may be unable to complete the BDC Election on the contemplated timeline or at all; (xiv) the risk that the Exchange Ratio, which will be determined based on the Closing Net Asset Value of each of LIEN and REFI calculated shortly prior to closing, may differ from current expectations or may not reflect changes in market conditions or portfolio values between signing and closing; (xv) the risk that the amount, timing or tax treatment of the Tax Dividends required to be paid by REFI prior to the BDC Election Time may differ from current expectations, or that REFI may lack sufficient liquidity to pay such dividends on the contemplated timeline; (xvi) the risk that the conversion of REFI from a REIT to a regulated investment company may give rise to corporate-level tax on built-in gains or other tax consequences that may differ from current expectations; (xvii) the risk that operating as a BDC under the Investment Company Act will subject the combined company to regulatory limitations, including with respect to leverage and affiliate transactions, that may adversely affect operating results or investment strategy; (xviii) the risk that the share repurchase program of up to $25.0 million that the LIEN Board of Directors has agreed to consider in good faith following the Closing may not be adoption, or, if adopted, may differ in size, scope, timing, or terms from current expectations; and (xix) other considerations that may be disclosed from time to time in publicly available documents filed by LIEN and REFI with the SEC. LIEN and REFI undertake no duty to update any forward-looking statements made herein.

No Offer or Solicitation

This press release is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the “Securities Act”), or in a transaction exempt from the registration requirements of the Securities Act.

Additional Information and Where to Find It

This communication relates to the proposed Merger involving LIEN and REFI, along with related proposals for which stockholder approval will be sought. The Merger Agreement was unanimously approved by the Boards of Directors of both LIEN and REFI, each acting on the unanimous recommendation of its respective Special Committee comprised solely of independent directors. In connection with the proposals, LIEN intends to file relevant materials with the SEC, including a registration statement on Form N-14, which will include a joint proxy statement of LIEN and REFI and a prospectus of LIEN (the “Proxy Statement/Prospectus”). This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act. STOCKHOLDERS OF LIEN AND REFI ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS, AND OTHER DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT LIEN, REFI, THE MERGER AND THE PROPOSALS. Investors and security holders will be able to obtain the documents filed with the SEC free of charge at the SEC's website, www.sec.gov, or from each company's investor relations website at www.investors.chicagoatlanticbdc.com (LIEN) and www.investors.refi.reit (REFI), or by directing a request to [email protected] (LIEN) or [email protected] (REFI).

Participants in the Solicitation

LIEN, REFI and their respective directors and executive officers, the LIEN Adviser and the Company Manager, and their respective directors, officers, members, managers, partners, employees and affiliates, and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of LIEN and REFI in connection with the Merger and the related proposals. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the stockholders of LIEN and REFI in connection with the Merger and the related proposals, including a description of their direct or indirect interests, by security holdings or otherwise, will be included in the Proxy Statement/Prospectus and other relevant materials to be filed with the SEC when they become available. Additional information regarding the ownership of LIEN and REFI securities by their respective directors and executive officers is included in such persons' SEC filings on Forms 3, 4 and 5, which can be found through the SEC's website at www.sec.gov. Information about the directors and executive officers of LIEN is also set forth in LIEN's proxy statement for its 2026 annual meeting of stockholders, filed with the SEC on April 30, 2026, and in LIEN's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 19, 2026. Information about the directors and executive officers of REFI is also set forth in REFI's proxy statement for its 2026 annual meeting of stockholders, filed with the SEC on April 23, 2026, and in REFI's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on March 12, 2026. Each of these documents is available free of charge at the SEC's website, www.sec.gov, or from LIEN's or REFI's investor relations website, as applicable.

Contacts:

Tripp Sullivan
Lisa Kampf
SCR Partners
[email protected]
[email protected]

1 Pro-forma information based on March 31, 2026 financial statements as reported on Form 10-Q.

Trinity Capital is a well-managed, internally managed BDC with a differentiated equipment financing focus and strong portfolio discipline. TRIN's fundamentals are robust, but recent non-accruals have re-accelerated, highlighting some credit risk beneath the surface. Shares trade at a historically rich premium (1.28x NAV, >8x NII), making the current valuation stretched relative to the sector and history.

On June 18, 2026, Floor & Decor Holdings Inc FND shares rose 5.9% to a current price of $53.03. This movement occurs within a 52-week range of $42.64 to $92.41, reflecting a significant volatility in the stock's performance over the past year.

GF Value™ verdict: Current price of $53.03 is 46.8% below the GF Value™ estimate of $99.74, indicating strong undervaluation.GF Score™: 81/100, which signifies a strong overall performance in key financial metrics.Most notable signal: Insider activity shows a net selling of $0.3M in the last 3 months, suggesting cautious sentiment among insiders. Is FND Overvalued or Undervalued? According to the GF Value™, Floor & Decor Holdings Inc is currently undervalued, with a significant margin of safety. The current market price of $53.03 is substantially lower than the estimated fair value of $99.74, which translates to a potential upside of 46.8%. This valuation suggests that, under normal market conditions, the stock has the potential to appreciate significantly if it approaches its intrinsic value. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.

The GF Valuation label indicates that FND is significantly undervalued, presenting an opportunity for investors who may be seeking stocks with strong upside potential. However, it is essential to consider market conditions and potential risks that could affect the stock's performance in the future.

How Does FND's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 28.8x 38.8x Forward P/E 27.6x N/A Floor & Decor's current P/E (TTM) of 28.8x is significantly below its 5-year median P/E of 38.8x, indicating that the stock is trading at a discount compared to its historical valuation. This analysis aligns with the GF Value™ verdict of being undervalued, as FND's current valuation multiples suggest that there may be room for growth in its stock price.

What Does FND's GF Score™ Tell Us? Metric Rating GF Score™ 81 Financial Strength 6/10 Profitability 8/10 Growth 8/10 Valuation 4/10 Momentum 4/10 The GF Score™ of 81/100 indicates that Floor & Decor Holdings Inc has strong overall performance, particularly in profitability and growth, where it scores 8/10. However, the lower scores in valuation (4/10) and momentum (4/10) highlight areas of concern that may affect future performance. The strong profitability and growth metrics suggest a solid operational foundation, while the valuation and momentum scores suggest that market sentiment may currently be unfavorable.

What Are Insiders Doing with FND Stock? In the past three months, insider trading activity has shown that insiders bought $0.4 million worth of stock while selling $0.7 million. This net selling of $0.3 million may indicate a cautious sentiment among insiders regarding the company’s short-term prospects. While insider selling can be a typical occurrence, it may also reflect a lack of confidence in immediate performance, warranting close monitoring as part of the investment evaluation.

What This Means for Investors Based on the GF Value™ assessment, Floor & Decor Holdings Inc is currently undervalued, presenting a potential opportunity for investors looking for growth stocks with strong upside potential. However, it is essential to consider the broader market conditions and the company’s recent performance trends before making any investment decisions.

For the complete analysis, visit the Floor & Decor Holdings Inc FND stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.

Frequently Asked Questions What is FND's GF Score™?

FND's GF Score™ is 81/100, indicating a strong overall performance based on various financial metrics, suggesting potential for higher long-term returns.

Is FND overvalued or undervalued?

FND is currently undervalued with a GF Value™ of $99.74, indicating a significant potential upside from its current price of $53.03.

What is FND's P/E ratio?

The P/E ratio for FND is 28.8x, which is 26% below its 5-year median P/E of 38.8x, suggesting that the stock is trading at a discount compared to its historical valuation.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

NEW YORK, June 17, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Kyndryl Holdings, Inc. (NYSE: KD) breached their fiduciary duties to shareholders.

According to a federal securities lawsuit, Kyndryl Holdings misrepresented or failed to disclose that: (1) certain members of executive management engaged in systematic manipulation of the Company's free cash flow metrics through the deliberate postponement of vendor payments from one fiscal quarter to the next; (2) as a consequence thereof, Kyndryl falsely represented its reported free cash flow metrics as indicative of the quality and long-term sustainability of its earnings and revenue growth, when in reality such cash generation was contingent upon undisclosed and inherently unsustainable cash management practices; (3) the Company's procedures governing financial disclosures, its accounting methodologies, and its internal controls over financial reporting were materially inadequate and deficient; and (4) by reason of the foregoing, Kyndryl's business operations, financial condition, and prospects for achieving profitable growth were materially worse than had been publicly represented to investors.

If you currently own KD and purchased prior to August 1, 2024 please contact Justin Kuehn, Esq. by email at [email protected] or call (833) 672-0814. Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

Why Your Participation Matters:

As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™

For additional information, please visit Shareholder Derivative Litigation - Kuehn Law.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts:
Kuehn Law, PLLC
Justin Kuehn, Esq.
53 Hill Street, Suite 605
Southampton, NY 11968
[email protected]
(833) 672-0814

Key Takeaways Synovis MCA entered a multi-year deal to commercialize SHIYA worldwide.BAX shares rose 2.6% after the news, with YTD gains of 4.1% against the industry's 24.1% fall.SHIYA offers 3D visualization, 20x magnification and wearable displays for microsurgical procedures. Synovis Micro Companies Alliance, Inc. (Synovis MCA), a subsidiary of Baxter International (BAX - Free Report) , recently entered into a multi-year distribution agreement with MediThinQ. Under the agreement, Synovis MCA will commercialize SHIYA, MediThinQ's next-generation 3D surgical visualization platform. The agreement aims to expand access to advanced digital surgical visualization technologies worldwide and support the evolution of microsurgery.

According to Michael Campbell, president of Synovis MCA, the company is honored to partner with MediThinQ as the global commercialization partner for SHIYA, a breakthrough digital surgical visualization technology. SHIYA aligns with the company's mission of being the microsurgeon's most trusted resource by delivering innovative solutions that are safer, efficient and effective.

BAX Stock Trend Following the NewsFollowing the announcement, BAX shares gained 2.6% at yesterday’s closing. In the year-to-date (YTD) period, shares of the company gained 4.1% against the industry’s 24.1% fall. However, the S&P 500 has risen 9.7% in the same timeframe.

The agreement strengthens Baxter's presence in the growing market for digital surgical technologies. Through Synovis MCA's microsurgery expertise, strong relationships and presence across major international markets, SHIYA is expected to gain broader global adoption. By adding SHIYA to its portfolio, Synovis MCA enhances its ability to offer advanced solutions for microsurgical procedures while supporting the industry's transition toward technology-driven surgical environments.

BAX currently has a market capitalization of $10.01 billion.

Image Source: Zacks Investment Research

More on the NewsSHIYA is a fully digital surgical visualization platform that combines a high-resolution 3D digital exoscope with up to 20x magnification and MediThinQ's proprietary wearable display, SCOPEYE. The platform allows surgeons to operate without traditional microscope eyepieces, improving ergonomics and enabling shared visibility across the surgical team.

Unlike conventional optical systems, SHIYA enables real-time capture, storage and sharing of surgical data, supporting future applications in artificial intelligence, advanced analytics and robotic-assisted surgery. The platform has already been used in more than 100 procedures globally and is supported by peer-reviewed research highlighting its clinical and ergonomic benefits.

The global rollout of SHIYA will be phased over time, with commercialization tailored to regulatory requirements and market readiness across different countries. Through this agreement, Synovis MCA will leverage its specialized commercial infrastructure and clinical expertise to accelerate the adoption of the platform worldwide.

Industry Prospects Favoring the MarketGoing by the data provided by Future Market Insights, the 3D imaging surgical solution market is valued at $172.6 million in 2026 and is estimated to grow at a CAGR of 6.3% from 2026 to 2035.

Factors like the rising demand for minimally invasive surgeries, growing adoption of robotic surgery and high-quality 3D imaging, and increasing focus on patient safety and surgical outcomes are boosting the market growth.

Other NewsBaxter continues to emphasize innovation as a key driver of long-term growth, underscored by recent product introductions such as the Dynamo smart hospital stretcher, Connex 360 connected-care platform, IV Verified automated medication labeling system and XR spine surgical table.

BAX’s Zacks Rank & Key PicksCurrently, BAX has a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Globus Medical (GMED - Free Report) and Biodesix (BDSX - Free Report) .

West Pharmaceutical, sporting a Zacks Rank #1 (Strong Buy) at present, reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical has an estimated long-term earnings growth rate of 13.9%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%.

Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%.

Globus Medical has an estimated long-term earnings growth rate of 10.2%. GMED’s earnings beat estimates in the trailing four quarters, the average surprise being 26.3%.

Biodesix, currently carrying a Zacks Rank of 2, reported a first-quarter 2026 adjusted loss per share of 81 cents, which was 35.71% narrower than the Zacks Consensus Estimate. Revenues of $26 million beat the Zacks Consensus Estimate by 12.3%.

BDSX has an estimated earnings growth rate of 36% for 2026. The company beat earnings estimates in three of the trailing four quarters and missed once, the average surprise being 25.6%.

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.

By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.

However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.

Our proprietary system currently recommends Ubiquiti Inc. (UI - Free Report) as one such stock. This company not only has a favorable Growth Score, but also carries a top Zacks Rank.

Research shows that stocks carrying the best growth features consistently beat the market. And for stocks that have a combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy), returns are even better.

While there are numerous reasons why the stock of this computer networking company is a great growth pick right now, we have highlighted three of the most important factors below:

Earnings GrowthArguably nothing is more important than earnings growth, as surging profit levels is what most investors are after. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.

While the historical EPS growth rate for Ubiquiti is 10%, investors should actually focus on the projected growth. The company's EPS is expected to grow 36.1% this year, crushing the industry average, which calls for EPS growth of 12.4%.

Impressive Asset Utilization RatioAsset utilization ratio -- also known as sales-to-total-assets (S/TA) ratio -- is often overlooked by investors, but it is an important indicator in growth investing. This metric shows how efficiently a firm is utilizing its assets to generate sales.

Right now, Ubiquiti has an S/TA ratio of 1.97, which means that the company gets $1.97 in sales for each dollar in assets. Comparing this to the industry average of 0.59, it can be said that the company is more efficient.

While the level of efficiency in generating sales matters a lot, so does the sales growth of a company. And Ubiquiti is well positioned from a sales growth perspective too. The company's sales are expected to grow 23.2% this year versus the industry average of 1.1%.

Promising Earnings Estimate RevisionsSuperiority of a stock in terms of the metrics outlined above can be further validated by looking at the trend in earnings estimate revisions. A positive trend is of course favorable here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

The current-year earnings estimates for Ubiquiti have been revising upward. The Zacks Consensus Estimate for the current year has surged 5.6% over the past month.

Bottom LineUbiquiti has not only earned a Growth Score of B based on a number of factors, including the ones discussed above, but it also carries a Zacks Rank #2 because of the positive earnings estimate revisions.

You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

This combination indicates that Ubiquiti is a potential outperformer and a solid choice for growth investors.

In its upcoming report, Darden Restaurants (DRI - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $3.63 per share, reflecting an increase of 21.8% compared to the same period last year. Revenues are forecasted to be $3.73 billion, representing a year-over-year increase of 14.1%.

The current level reflects an upward revision of 1.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.

Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.

While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.

Bearing this in mind, let's now explore the average estimates of specific Darden Restaurants metrics that are commonly monitored and projected by Wall Street analysts.

The consensus estimate for 'Sales- Olive Garden' stands at $1.55 billion. The estimate indicates a year-over-year change of +12.1%.

Analysts predict that the 'Sales- Other Business' will reach $803.58 million. The estimate suggests a change of +11.3% year over year.

The consensus among analysts is that 'Sales- Fine Dining' will reach $379.38 million. The estimate indicates a change of +13.4% from the prior-year quarter.

Based on the collective assessment of analysts, 'Sales- LongHorn Steakhouse' should arrive at $976.58 million. The estimate indicates a change of +17.1% from the prior-year quarter.

Analysts expect 'Same-restaurant sales - LongHorn Steakhouse - YoY change' to come in at 6.6%. Compared to the present estimate, the company reported 6.7% in the same quarter last year.

It is projected by analysts that the 'Company-owned restaurants - Olive Garden' will reach 954 . Compared to the present estimate, the company reported 935 in the same quarter last year.

The combined assessment of analysts suggests that 'Same-restaurant sales - Olive Garden - YoY change' will likely reach 3.2%. Compared to the present estimate, the company reported 6.9% in the same quarter last year.

According to the collective judgment of analysts, 'Same-restaurant sales - Consolidated - YoY change' should come in at 4.1%. Compared to the present estimate, the company reported 4.6% in the same quarter last year.

The average prediction of analysts places 'Company-owned restaurants - LongHorn Steakhouse' at 618 . Compared to the present estimate, the company reported 591 in the same quarter last year.

Analysts' assessment points toward 'Company-owned restaurants - Total' reaching 2,216 . Compared to the present estimate, the company reported 2,159 in the same quarter last year.

The collective assessment of analysts points to an estimated 'Company-owned restaurants - Ruth's Chris Steak House' of 83 . The estimate is in contrast to the year-ago figure of 82 .

Analysts forecast 'Company-owned restaurants - Bahama Breeze' to reach 20 . The estimate compares to the year-ago value of 28 .

View all Key Company Metrics for Darden Restaurants here>>>

Darden Restaurants shares have witnessed a change of +8.3% in the past month, in contrast to the Zacks S&P 500 composite's +1.4% move. With a Zacks Rank #3 (Hold), DRI is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Premier American Uranium Inc. (“PUR”, the “Company” or “Premier American Uranium”) (TSXV: PUR) (OTCQB: PAUIF) is pleased to announce preliminary results from the 2026 exploration drilling program at the Company’s wholly-owned Kaycee Project (“Kaycee” or the “Project”), located in the Powder River Basin (“PRB”) of northeastern Wyoming. Drilling commenced at the Outpost target in May 2026. To date, 19 drillholes have been completed for a total of 17,100 ft of drilling. A total of 100,000 ft of drilling is currently planned for the 2026 season, with specific focus on the Outpost, Rustler, and Stampede exploration areas (Figure 1).

Highlights

Infill and step-out drilling in the Outpost (Figure 2) area has expanded and further defined the zone of known uranium mineralization. Nineteen conventional mud rotary holes have been completed for a total of 17,100 ft of drilling in 2026 (Figure 1).Seven of the 19 drill holes intersected uranium mineralization at grades of 0.02% eU₃O₈ or higher (see Table 1 for significant intercepts).Drilling results to date provide valuable lithologic information to support geologic interpretation and guide future exploration plans. Drilling has identified two target sand units within the lower Wasatch Formation, both of which are host to uranium mineralization. The lower Wasatch Formation is also the principal host of uranium mineralization in the Pumpkin Buttes district, just east of the Kaycee Project area.In conjunction with the drilling program, the Company engaged a professional surveying contractor to complete a Project-wide drillhole collar and elevation survey. This survey work is complete, and the results will be used to support future mineral resource estimation initiatives and ongoing technical evaluation of the Project. Colin Healey, CEO of PUR commented, "These initial results continue to highlight the exploration potential of the Kaycee Project and reinforce our view that the district hosts multiple areas capable of generating meaningful uranium resources. The expansion of mineralization at Outpost, together with the geological insights gained from drilling, is improving our understanding of the controls on mineralization and helping refine targeting across the broader district.

We began the 2026 program at Outpost due to seasonal accessibility and the compelling results generated from its discovery during the 2025 campaign. As a newly identified uranium-bearing system that remains in the early stages of exploration, Outpost has delivered encouraging results that support further follow-up work. With only a small portion of our planned 100,000-foot drill program completed, we are pleased with the progress to date and look forward to advancing drilling at Outpost while continuing to test the significant potential of the Rustler and Stampede target areas throughout the season."

Table 1. 2026 Kaycee Significant Intercepts

DrillholeInterceptFrom
(ft) To
(ft) Length
(ft) eU₃O₈
% LT26-074intersected214.5 215.5 1 0.052  and798.5 800.5 2 0.036 LT26-076intersected802 805 3 0.022  including803 804.5 1.5 0.03 LT26-077intersected792.5 794.5 2 0.073  including793 793.5 0.5 0.101 LT26-078intersected748 749 1 0.029 LT26-079intersected771.5 772.5 1 0.022  and787 789 2 0.027 LT26-083intersected773 774 1 0.026 LT26-086intersected793 793.5 0.5 0.026            Notes: Drill holes reported here encountered uranium mineralization at or above a cut-off grade of 0.02% eU₃O₈. All grades were calculated from gamma-ray logs measured by Hawkins CBM Logging of Casper, Wyoming, which is independent of the Company. The geophysical results are based on equivalent uranium (eU3O8) of the gamma-ray probes which are calibrated at the Department of Energy’s test facility in Casper, Wyoming. Uranium grades cited are calculated from gamma-ray logs, and the cited grades are “equivalent” (“e”) grades of U₃O₈ %. eU₃O₈ is a measure of gamma intensity from a decay product of uranium and is not a direct measurement of uranium. No corrections were made for radiometric disequilibrium. Numerous comparisons of eU₃O₈ and chemical assays of PRB core samples indicate that eU₃O₈ is a reasonable indicator of the actual uranium assay. All drill holes are vertical in orientation and the geologic units hosting the uranium mineralization are generally very flat lying, therefore reported thicknesses represent true thicknesses.

Figure 1. Kaycee Project Key Targets in 2026

Figure 2. Kaycee Project 2026 Drill Holes

Kaycee Project

The Kaycee Project in Wyoming's Powder River Basin consists of over 42 square miles of mineral rights over a 36-mile mineralized trend hosting more than 110 miles of identified roll fronts (Figure 3). The Project is believed to be the only project in the PRB where all three known historically productive sandstone formations (Wasatch, Fort Union, and Lance) are mineralized and potentially accessible for ISR extraction. The Project represents the largest grass-roots ISR exploration in the United States, with upwards of 400,000 ft of drilling completed since 2023.

PUR anchors one of the strongest exploration portfolios in Wyoming, combining its Cyclone Project in the Great Divide Basin with Kaycee to drive one of the largest ongoing drilling programs in the state and significantly expand its presence in both of the state’s major ISR-amenable uranium districts.

Figure 3. PUR’s Wyoming exploration portfolio, highlighting the Kaycee Project in the Powder River Basin and the Cyclone Project in the Great Divide Basin. Active exploration is currently underway at both projects.

Qualified Person Statement

The scientific and technical information contained in this news release was reviewed and approved by J.J. Brown, P.G., SME-RM, PUR’s Vice President, Exploration, who is a “Qualified Person” as defined by National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Ms. Brown has verified the data disclosed in this news release, including sampling, analytical, and test data underlying the information contained herein.

The drilling results cited in this news release were derived from conventional mud rotary drill holes and continuously recorded geophysical responses (gamma-ray, spontaneous-potential, and single point resistivity) from a borehole geophysical probe. The mineralized zones are flat lying and the individual drill holes are vertical in orientation, and the thicknesses cited in this release are considered to be true thicknesses. Grades of mineralization reported were calculated from the gamma-ray logs following a procedure that was first developed in the early 1960s and is standard practice in the uranium industry. The borehole geophysical logging was carried out by Hawkins CBM Logging of Casper, Wyoming, a highly experienced and skilled geophysical contractor with a well-established history of providing reliable and accurate data.

Other information regarding the Company’s Kaycee Project, including with respect to the Quality Assurance and Quality Control measures applied during the work program can be referenced from the “Technical Report for NI 43-101 Kaycee Uranium Project, Johnson County, Wyoming USA”, dated September 21, 2025, which is available under the Company’s profile on SEDAR +, at www.sedarplus.ca.

About Premier American Uranium Inc.

Premier American Uranium is focused on consolidating, exploring, and developing uranium projects across the United States to strengthen domestic energy security and advance the transition to clean energy. The Company’s extensive land position spans five of the nation’s top uranium districts, with active work programs underway in New Mexico’s Grants Mineral Belt and Wyoming’s Great Divide and Powder River Basins.

Backed by strategic partners including Sachem Cove Partners, IsoEnergy Ltd., Mega Uranium Ltd., and other leading institutional investors, PUR is advancing a portfolio supported by defined resources and high-priority exploration and development targets. Led by a distinguished team with deep expertise in uranium exploration, development, permitting, operations, and uranium-focused M&A, the Company is well positioned as a key player in advancing the U.S. uranium sector.

For More Information, Please Contact:

Premier American Uranium Inc.
Colin Healey, CEO

[email protected]
Toll-Free: 1-833-223-4673
Twitter: @PremierAUranium
www.premierur.com

Neither TSX Venture Exchange nor its Regulations Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities laws. Forward-looking information includes, but is not limited to, statements with respect to, additional exploration activities planned for 2026, the anticipated results thereof and the anticipating timing for reporting of such results; future prospects for exploration; the potential for mineral resource identification at the Project; expectations regarding the transition to clean energy in the US; and other activities, events or developments that are expected, anticipated or may occur in the future. Generally, but not always, forward-looking information and statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or the negative connotation thereof or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof.

Forward-looking information and statements are based on our current expectations, beliefs, assumptions, estimates and forecasts about PUR’s business and the industry and markets in which it operates. Such forward-information and statements are based on numerous assumptions, including among others, that the results of planned exploration activities are as anticipated, the price of uranium, the anticipated cost of planned exploration activities, the completion, timing and results of planned exploration activities being consistent with expectations, the anticipated mineralization being consistent with expectations, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms, that third party contractors, equipment and supplies and governmental and other approvals required to conduct the Company’s planned exploration activities will be available on reasonable terms and in a timely manner. Although the assumptions made by PUR in providing forward-looking information or making forward-looking statements are considered reasonable by management at the time, there can be no assurance that such assumptions will prove to be accurate.

Forward-looking information and statements also involve known and unknown risks and uncertainties and other factors, which may cause actual results, performances and achievements of Premier American Uranium to differ materially from any projections of results, performances and achievements of Premier American Uranium expressed or implied by such forward-looking information or statements, including, among others: limited operating history, negative operating cash flow and dependence on third party financing, uncertainty of additional financing, delays or failure to obtain required permits and regulatory approvals, changes in mineral resources, no known mineral reserves, aboriginal title and consultation issues, reliance on key management and other personnel; potential downturns in economic conditions; availability of third party contractors; availability of equipment and supplies; failure of equipment to operate as anticipated; accidents, effects of weather and other natural phenomena and other risks associated with the mineral exploration industry; changes in laws and regulation, competition, and uninsurable risks and the risk factors with respect to Premier American Uranium set out in the documents of PUR filed with the Canadian securities regulators and available under PUR’s profile on SEDAR+ at www.sedarplus.ca.

Although PUR has attempted to identify important factors that could cause actual actions, events or results to differ materially from those contained in the forward-looking information or implied by forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on forward-looking statements or information. PUR undertakes no obligation to update or reissue forward-looking information as a result of new information or events except as required by applicable securities laws.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/7063f958-e7f2-4c64-8c55-75be175ce439
https://www.globenewswire.com/NewsRoom/AttachmentNg/22f33737-83ba-4636-a738-98357868658d
https://www.globenewswire.com/NewsRoom/AttachmentNg/31eb444e-abcf-492f-8274-d61151d749c6

Press Release

Atos powers kick-off of new football season as 2026-27 Premier League fixtures revealed

London, UK – June 19, 2026 – Atos, a global leader in AI-powered digital transformation, has worked in close collaboration with the Premier League since its inception in 1992, scheduling the Premier League’s fixtures each season. 

Across 34 complete Premier League seasons, Atos has supported the complex challenge of creating a balanced fixture list across a total of 13,166 matches involving 51 different clubs. Advanced technology is combined with deep human expertise to assess millions of possible scenarios, ensuring the final schedule is fair, competitive and compelling for clubs, fans and stakeholders alike. 

The process begins at the start of the year and typically takes around six months. Sophisticated systems generate an initial schedule, which is then rigorously refined through expert oversight to meet the league’s strict sporting, operational and logistical requirements - following the League’s “Golden Rules”. These include: 

In any five matches there should be a split of three home fixtures, two away or the other way around.  A team will never have more than two home or away matches in a row. Wherever possible, a team will be home and away around FA Cup ties.  A club will never start or finish the season with two home or two away matches.  Alongside this are considerations around preventing local rivals from playing at home on the same day, accounting for policing capacity, and managing travel demands—particularly during peak periods such as public holidays or major national events, for example minimising travel for fans on Boxing Day and New Year's Day. 

Even minor changes can have wide-ranging consequences, often triggering adjustments across multiple fixtures. This is where Atos’ long-standing experience is critical.  

Fixture-list compiler Glenn Thompson, Atos UK&I, said: “There are pinch points in the process where it can become stressful, culminating in several days in a room manually checking for any issues that may have cropped up. The whole process is complex involving many different data points. Ultimately you can't satisfy everyone and it's a compromise across all clubs without favouring any one club.”  

This year’s fixture list has also been shaped against an increasingly demanding global football calendar, with a focus on player welfare, recovery time and alignment with international competitions. 

Michael Herron, Head of Atos UK&I said, “For millions of fans, the release of the Premier League fixture list is when a new season really comes to life. We’re proud to support the Premier League and are looking forward to another exciting season ahead.”  

Atos has maintained a dedicated Sports and Major Events division for more than 30 years. This experience in delivering innovative solutions for the world’s most prestigious competitions enables Atos to provide the flexibility and technological excellence required for all types of events — from local tournaments to major global showcases. Leading this commitment is its role as UEFA’s Official IT Partner for National Team Football since late 2022, as well as its long-standing relationship with many other sports international organizations. Most recently, Atos became CONMEBOL’s Official Innovation Partner, which will focus on South American football’s domestic-club competitions. 

*** 

About Atos Group 

Atos Group is a global leader in digital transformation with c. 56,000 employees and annual revenue of c. €7.2 billion (at the go-forward perimeter), operating in 54 countries under two brands – Atos for services and Eviden for products and systems. European number one in cybersecurity and a leader in cloud, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos Group is listed on Euronext Paris. 

Press contact 

Tessa David – [email protected] - 07947 755 911 

Atos PL Fixtures PR 2026

LifeStance Health Group (LFST - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.

Therefore, the Zacks rating upgrade for LifeStance Health basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For LifeStance Health, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for LifeStance HealthFor the fiscal year ending December 2026, this outpatient mental health services provider is expected to earn $0.12 per share, which is unchanged compared with the year-ago reported number.

Analysts have been steadily raising their estimates for LifeStance Health. Over the past three months, the Zacks Consensus Estimate for the company has increased 42.3%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of LifeStance Health to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Key Takeaways BEAM shares rose 5% after the FDA cleared the IND for BEAM-304, a gene-editing therapy for PKU.BEAM-304 targets PAH gene mutations to lower toxic Phe levels and restore PAH function.BEAM plans to initiate a phase I/II study & later expand the program to target a second mutation. Shares of Beam Therapeutics (BEAM - Free Report) rose 5% on Thursday after the FDA cleared the investigational new drug (IND) application for BEAM-304, the company’s investigational gene-editing therapy for the treatment of phenylketonuria (PKU). The clearance marks an important milestone for Beam Therapeutics as it expands its liver-targeted genetic disease franchise.

PKU is a rare inherited metabolic disorder characterized by the inability to properly break down phenylalanine (Phe), resulting in its toxic buildup in the body. If left untreated, elevated Phe levels can lead to serious neurological and cognitive complications, requiring patients to adhere to strict lifelong dietary restrictions.The disease affects approximately 20,000 people in the United States and is typically diagnosed through newborn screening. Currently, no approved curative treatments exist for PKU.

Year to date, the stock has risen 23.2% against the industry’s 1% decline.

Image Source: Zacks Investment Research

More on Beam Therapeutics’ BEAM-304BEAM-304 is a liver-targeted, lipid nanoparticle (LNP)-based gene-editing therapy designed to correct disease-causing mutations in the phenylalanine hydroxylase (PAH) gene responsible for PKU. By restoring PAH function, the therapy aims to lower toxic Phe levels, potentially allowing patients to maintain a normal diet without relying on specialized medical foods.

The candidate is being developed using an innovative approach that enables efficient evaluation of multiple mutation-specific base editors within a single clinical program through in vivo delivery. This strategy aligns with the FDA’s efforts to accelerate the development of genome-editing treatments for serious genetic diseases.

In preclinical studies, BEAM-304 demonstrated robust on-target liver editing and normalization of Phe levels in PKU mouse models at clinically relevant doses, supporting its potential as a disease-modifying therapy.

Beam plans to evaluate BEAM-304 in a phase I/II open-label clinical study designed to initially assess the safety, tolerability, blood Phe reduction and the potential for dietary liberalization of BEAM-304 in PKU patients with the R408W mutation. The therapy will be administered as an intravenous infusion. The program will then expand to evaluate a base editor targeting a second mutation, with the aim of establishing clinical proof of concept for base editing in PKU.

BEAM’s Zacks Rank & Stocks to ConsiderBeam Therapeutics currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) , Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share estimates for Indivior Pharmaceuticals remained unchanged at $4.05 for 2026 and $4.27 for 2027. INDV shares have risen 6.7% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

Over the past 30 days, estimates for Liquidia’s earnings per share remained unchanged at $2.97 for 2026 and $4.81 for 2027. LQDA shares have surged 106.1% year to date.

Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 30 days, earnings per share estimates for Immunocore’s 2026 were unchanged at 6 cents for 2026 and 87 cents for 2027. IMCR shares have lost 17.6% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 46.66%.

Notice to Pension Funds, Asset Managers, and Fiduciaries: FS KKR Capital Corp. Portfolio Losses Totaling $880 Million Across Two Corrective Disclosures May Trigger Fiduciary Review Obligations for Institutional Holders

, /PRNewswire/ -- Institutional investors holding positions in FS KKR Capital Corp. (NYSE: FSK) during the period May 8, 2024 through February 25, 2026 may wish to evaluate lead plaintiff opportunities in the pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

FSK shares fell $2.03 per share, or 15.24%, closing at $11.29 on February 26, 2026, after the Company cut its quarterly dividend from $0.70 to $0.48 and disclosed that non-accrual investments had risen above the long-term BDC industry average. Combined fair value declines across Q2 and Q4 2025 totaled approximately $880 million.

Notice to Institutional Holders

Pension funds, endowments, mutual funds, and other fiduciaries that acquired FSK shares during the Class Period face distinct considerations. Under ERISA and analogous state fiduciary standards, investment managers who held FSK in client portfolios may need to assess whether continued retention of the position, failure to monitor corrective disclosures, or inaction regarding lead plaintiff appointment could raise fiduciary questions.

Institutional holders with the largest documented losses are frequently best positioned to serve as lead plaintiff, giving them direct oversight of litigation strategy, settlement negotiations, and counsel selection.

Fiduciary Obligations and Recovery Options

The lawsuit asserts that FS KKR Capital and certain officers made materially misleading statements about portfolio health, restructuring progress, and distribution sustainability throughout the Class Period. Institutional investors should consider:

FSK's net asset value declined from $24.32 per share (Q1 2024) to $20.89 per share (Q4 2025), a cumulative erosion of $3.43 per share, or 14.1%, across the period Total fair value of investments fell $474 million in Q2 2025 and an additional $406 million in Q4 2025 The Company's dividend was cut by 31.4%, from $0.70 to $0.48 per share, directly affecting income-dependent institutional portfolios Lead plaintiff appointment carries no additional cost and provides governance authority over case strategy Contact us for institutional recovery options or call (212) 363-7500.

Portfolio Impact Assessment

BDC allocations are frequently held within income-focused mandates where distribution stability is a core selection criterion. The complaint contends that management repeatedly assured shareholders that distributions were sustainable and backed by spillover income, even as the underlying portfolio deteriorated. For fiduciaries who selected or retained FSK based on these representations, the corrective disclosures may have caused losses that warrant formal review under applicable fiduciary standards.

"Institutional investors play a critical role in securities class actions. Their participation as lead plaintiff ensures the class benefits from experienced oversight and meaningful accountability," stated Joseph E. Levi, Esq.

Case Summary

The action alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5. The Class Period runs from May 8, 2024 through February 25, 2026. The Court has set July 6, 2026 as the deadline to apply for lead plaintiff appointment.

INSTITUTIONAL INVESTOR REPRESENTATION Levi & Korsinsky, LLP provides sophisticated counsel to institutional investors evaluating lead plaintiff opportunities. The firm has recovered hundreds of millions of dollars. Ranked among ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the FSK Lawsuit

Q: Who is eligible to join the FSK investor lawsuit? A: Investors who purchased FSK stock or securities between May 8, 2024 and February 25, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: What is the FSK lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is July 6, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: How do I know if I lost enough money to be the lead plaintiff? A: There is no minimum loss threshold. Courts appoint the investor with the largest provable loss who is willing and able to represent the class adequately. Contact Levi & Korsinsky before July 6, 2026 to evaluate.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I already sold my FSK shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What if I live outside the United States? A: U.S. securities class actions generally cover purchases on U.S. exchanges regardless of investor's country of residence.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

SOURCE Levi & Korsinsky, LLP

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of FS KKR Capital Corp. (NYSE: FSK) between May 8, 2024 and February 25, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.

So what: If you purchased FS KKR Capital securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the FS KKR Capital class action, go to https://rosenlegal.com/submit-form/?case_id=64089 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) FS KKR Capital overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) FS KKR Capital overstated the valuation of its portfolio investments and/or overstated the effectiveness of FS KKR Capital's portfolio valuation process; (3) FS KKR Capital overstated the durability of its quarterly distribution strategy; and (4) as a result of the foregoing, defendants' positive statements about FS KKR Capital's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the FS KKR Capital class action, go to https://rosenlegal.com/submit-form/?case_id=64089 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

FSK has been cut in half over twelve months and now trades at 0.59x NAV (net asset value) driven by the legacy 2021–2022 names, compared to the BDC group average. A $150mm KKR tender at $11.00, a $150mm convertible preferred struck at NAV ($18.83), a $300mm common buyback, and a four-quarter 50% waiver of the incentive fee were announced. I modeled the next four quarters bottom-up, portfolio roll-forward, mix, income build, debt stack, NAV bridge, on deliberately punitive credit assumptions.

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FS KKR Capital Corp. ("FSK KRR" or the "Company") (NYSE: FSK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

The class action concerns whether FSK KRR and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

You have July 3, 2026, to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired FSK KRR securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.   

[Click here for information about joining the class action]  

On August 6, 2025, the Company reported second quarter 2025 earnings, revealing that the Company's net asset value had declined to $21.93 per share, down $1.44, or 6.2% from the prior quarter, and the total fair value of investments fell $474 million, to $13,648 million.  Moreover, the Company report earnings (loss) per share of negative $0.75, down $1.18 or 274.4% from the prior quarter, and a total net realized and unrealized loss per share of negative $1.36, down $1.12 or 466.7% from the prior quarter.  Further, investments on non-accrual status rose to 3.0% and 5.3% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.1% and 3.5% in the prior quarter.  

On this news, FS KKR's stock price fell $1.66 per share, or 8.2%, to close at $18.58 per share on August 7, 2025. 

Then, on February 25, 2026, the Company announced fourth quarter and full year 2025 earnings, revealing net asset value had continued to decline to $20.89, down $1.10 or 5% from prior quarter, and the total fair value of investments fell another $406 million, to $13,009 million.  Moreover, the Company reported earnings (loss) per share of negative $0.41, down $1.17 or 153.9% from the prior quarter, and a total net realized and unrealized loss per share of negative $0.89, down $1.08 or 568.421% from the prior quarter.  Further, investments on non-accrual status again rose to 3.4% and 5.5% of the total investment portfolio at fair value and amortized cost, respectively, compared to 2.9% and 5.0% in the prior quarter.  The Company also "acknowledge[d] specific challenges" with additional companies and cut its dividend to $0.48 per share (previously $0.70). 

On this news, FS KKR's stock price fell $2.03 per share, or 15.24%, to close at $11.29 per share on February 26, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. 

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980 

SOURCE Pomerantz LLP

New York, New York--(Newsfile Corp. - June 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of FS KKR Capital Corp. (NYSE: FSK) between May 8, 2024 and February 25, 2026, inclusive (the "Class Period"), of the important July 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased FS KKR Capital securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the FS KKR Capital class action, go to https://rosenlegal.com/submit-form/?case_id=64089 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) FS KKR Capital overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; (2) FS KKR Capital overstated the valuation of its portfolio investments and/or overstated the effectiveness of FS KKR Capital's portfolio valuation process; (3) FS KKR Capital overstated the durability of its quarterly distribution strategy; and (4) as a result of the foregoing, defendants' positive statements about FS KKR Capital's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the FS KKR Capital class action, go to https://rosenlegal.com/submit-form/?case_id=64089 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302053

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against FS KKR Capital Corp. (NYSE: FSK) and certain of its officers.

This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired FS KKR Capital securities between May 8, 2024 and February 25, 2026, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/FSK.

FS KKR Capital Case Details

The Complaint alleges that throughout the Class Period, Defendants failed to disclose to investors that: 
   (1) the Company overstated the effectiveness of its portfolio restructuring efforts for its nonaccrual companies; 
   (2) the Company overstated the valuation of its portfolio investments and/or overstated the effectiveness of the Company’s portfolio valuation process;
   (3) the Company overstated the durability of its quarterly distribution strategy; and
   (4) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

What's Next for FS KKR Capital Investors?

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/FSK. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in FS KKR Capital you have until July 3, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.

No Cost to FS KKR Capital Investors

We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for FS KKR Capital Securities Class Action?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.

-

Co-developed with specialty providers, the solution reflects continued investment in workflow efficiency, data visibility and practice performance

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global pharmaceutical solutions company, today announced a multi-site pilot of its enhanced Nucleus® inventory management solution, designed to help specialty physician practices manage increasingly complex medication workflows with greater efficiency, visibility and control.

Developed with input from customer advisory boards and specialty care providers, the updated platform combines redesigned physical infrastructure with software and interface enhancements. The enhanced solution – which will be deployed in phases across more than 20 practice sites – is designed to improve visibility into inventory and patient-specific medication needs and support more coordinated workflows from ordering and tracking through storage and administration.

“The way inventory moves through a practice has a direct impact on both operational performance and patient care,” said Lisa Smith, SVP and President of Specialty Distribution and Solutions at Cencora. “Working alongside pharmacy and clinical teams, we co-developed the next generation Nucleus to streamline their experience while strengthening the solutions and infrastructure that support their day-to-day decision-making.”

Key features of the enhanced Nucleus solution include:

A modular cabinet design configured to support different workflows and practice needs; A larger integrated touchscreen to improve visibility into patient and inventory data; Built-in workspace enhancements that streamline the handling of physical inventory; and A more unified interface designed to reduce complexity, shorten training time and improve consistency for clinical and administrative teams. These enhancements build on Nucleus’ core functionality, which includes real-time inventory tracking, demand forecasting, automated billing support and access to a robust set of reporting tools that help practices manage cost, utilization and performance.

“As specialty therapies continue to evolve at a rapid pace, clinical care teams are managing increasing levels of complexity across clinical, financial and operational workflows,” said Camilo Rodriguez, Director of Pharmacy Operations at American Oncology Network and Cencora Advisory Board member. “By enhancing the infrastructure that supports inventory management, Cencora continues to collaboratively address providers’ unmet needs. The enhancements to Nucleus are designed to help practices operate more efficiently and maintain focus on delivering high-quality patient care.”

The pilot program will allow Cencora to evaluate system performance across a range of practice settings and gather feedback to inform broader deployment. Pending pilot outcomes, Cencora expects to begin scaling production and installation later this year, with expanded availability planned for existing and new customers.

To learn more about Cencora’s inventory management solutions, please visit the website here.

About Cencora
Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products and solutions. Our 51,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #17 on the Global Fortune 500 with more than $300 billion in annual revenue.

More News From Cencora

Back to Newsroom